UnitedHealthcare Discogenic Pain Coverage Update

Coverage Rationale and Determinations

Unproven / Not Medically Necessary

The following interventions are considered unproven and not medically necessary due to insufficient evidence of efficacy:

Unproven interventions: Annular closure devices (ACDs); Percutaneous injection of allogeneic cellular/tissue-based products; Thermal intradiscal procedures (TIPs) for treating discogenic pain are considered unproven and not medically necessary due to insufficient evidence of efficacy.

Coverage Rationale explicitly lists these as unproven/not medically necessary.

Annular Closure Devices (ACD)

Evidence summary and implied coverage considerations

Annular Closure Devices: Randomized evidence (Thomé et al.) showed reduced recurrent herniation and fewer reoperations in patients with large post-discectomy annular defects (6–10 mm width) randomized to a bone‑anchored annular closure device versus microdiscectomy alone; secondary analyses reported increased vertebral endplate changes (VEPC) with the device but overall fewer device- or procedure-related serious adverse events and fewer secondary surgical interventions in the ACD group. However, the body of evidence is limited by low overall quality, industry sponsorship, lack of blinding, selected patient characteristics (adequate disc height, non-osteoporotic bone), and insufficient long-term independent data. FDA premarket approval for the Barricaid device is limited to skeletally mature patients after primary discectomy at L4–S1 with an annular defect between 4–6 mm tall and 6–10 mm wide.anatomic defect size per FDA indication

ACD evidence is promising in selected high‑risk post‑discectomy patients but additional independent RCTs and longer follow‑up are needed.

Percutaneous injection of allogeneic cellular/tissue-based products

Percutaneous allogeneic intradiscal injections — evidence appraisal

Allogeneic intradiscal injections: Systematic reviews and independent evidence assessments (Hayes, ECRI) identify only a small number of trials, including a single fair‑quality randomized trial and several feasibility or single‑arm studies. RCT data (Beall et al./VAST) showed no clear, consistent patient‑oriented benefit versus placebo at up to 12 months for key outcomes; other small studies report improvements but are limited by small size, crossover, loss to follow‑up, and lack of independent replication. Overall, evidence is insufficient to establish safety and efficacy for routine clinical use.

Considered investigational/insufficient; further robust, independent RCTs with longer follow‑up required.

Thermal intradiscal procedures (IDET/IDB/PIRFT)

Thermal intradiscal procedures (IDET, IDB, PIRFT) — evidence synthesis

Thermal intradiscal procedures: The evidence base includes small RCTs, single‑center case series, and systematic reviews. Some RCTs and a systematic review report benefit for intradiscal biacuplasty (IDB) while evidence for IDET is mixed; PIRFT trials (e.g., discTRODE) failed to demonstrate consistent benefit versus sham. Limitations across studies include small sample sizes, single‑center designs, short follow‑up, potential placebo effects, and heterogeneity in patient selection and techniques. Overall, evidence is inconsistent and insufficient to support routine use except possibly in narrowly defined populations studied in positive trials.

Additional large, blinded RCTs with standardized selection criteria and long‑term outcomes are needed.

Covered and not-covered procedural groups

Coverage and evidence summary

PIRFT/intradiscal thermal therapies: Randomized and controlled trials and systematic reviews provide limited, inconsistent, or insufficient evidence of efficacy for PIRFT and similar intradiscal thermal procedures; some small case series report benefit but are limited by size and design. Professional guidance (NICE, NASS) finds the evidence low‑quality or insufficient and encourages further research rather than routine adoption.evidence insufficient

Kvarstein RCT found no difference versus sham at 6 months; later within‑group reductions did not show between‑group benefit.

Annular closure device (Barricaid): Multiple studies and meta‑analyses, and an ISASS 2025 review, report reductions in recurrent lumbar disc herniation (LDH) and reoperation with bone‑anchored annular closure in patients with large annular defects following primary discectomy. The FDA granted premarket approval for Barricaid for skeletally mature patients with a single‑level L4–S1 large annular defect (4–6 mm tall and 6–10 mm wide). Despite favorable results in selected high‑risk patients, overall evidence quality is limited and selection criteria from trials should guide use.anatomic defect size per FDA indication

ISASS supports use in select patients; routine use outside these indications and populations is not supported by high‑quality, independent long‑term data.

The following interventions are designated unproven and not medically necessary for the treatment of discogenic low back pain due to insufficient evidence of efficacy: annular closure devices (ACDs), percutaneous injection of allogeneic cellular/tissue-based products, and thermal intradiscal procedures (TIPs). This designation reflects the policy’s appraisal that current randomized and nonrandomized studies do not provide adequate, consistent patient‑oriented benefit to support routine coverage.

There is insufficient high‑quality evidence to support percutaneous intradiscal injection of donor‑derived (allogeneic) cellular/tissue products for discogenic pain; robust RCTs with larger samples and longer follow‑up are needed. Similarly, many thermal intradiscal procedures (including IDET, IDB, and related techniques) lack consistent, high‑quality evidence demonstrating efficacy and therefore are not supported for routine coverage outside of research settings.

Specific intra‑annular thermal techniques warrant caution: randomized evidence of PIRFT with the discTRODE probe did not show benefit versus sham at planned interim analysis and authors advised against intra‑annular discTRODE use given reported increased pain in some participants. Small case series of bipolar radiofrequency thermocoagulation and pilot device studies report within‑group improvements but are limited by small size, lack of controls, and short follow‑up.

In summary, annular closure devices, percutaneous allogeneic intradiscal injections, and thermal intradiscal procedures are each associated with evidence limitations: ACDs have some randomized data in selected post‑discectomy patients but overall trial limitations; allogeneic injections have only small RCTs and single‑arm studies with inconsistent results; and TIPs show mixed, low‑quality, or negative randomized data. Collectively, these limitations justify classifying these interventions as unproven for broad clinical use.

Use of intradiscal allogeneic cellular/tissue-based products and most intradiscal thermal procedures for discogenic pain is considered investigational/experimental because available studies do not reliably demonstrate safety and effectiveness; requests for these services should be supported by high‑quality evidence or considered only in research contexts.

Percutaneous intradiscal radiofrequency thermocoagulation (RFTC/PIRFT) and other intradiscal thermal or electrothermal therapies are designated not medically necessary for routine treatment of chronic discogenic low back pain due to inconsistent and low‑quality efficacy data and guideline statements that do not support routine use.

Applicable Procedure and Billing Codes

Allogeneic intradiscal injection CPT/T codesCPT

0627T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; first level.
0628T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure).
0629T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; first level.
0630T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure).

Thermal intradiscal and related spine procedure codesmixed

22526	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single level.
22527	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; 1 or more additional levels (List separately in addition to code for primary procedure).
22899	Unlisted procedure, spine.
63032	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; with repair of annular defect by implantation of bone-anchored annular closure device, including all imaging guidance, 1 interspace, lumbar (List separately in addition to code for primary procedure).
S2348	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar.

Applicable CPT codes (updated)CPT

63032

Added CPT code referenced in policy history (exact description as per CPT not provided in this section)

Prior Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior Authorization Required

Prior authorization may be required for certain intradiscal procedures. Providers should verify prior authorization (PA) requirements with the member's plan before scheduling services and include all relevant clinical documentation when requesting PA.

Verify PA requirements for new or updated CPT/HCPCS codes before claim submission.
When PA is required, submit documentation of indication, imaging, prior conservative management, and procedure codes.
Providers should document the specific procedure and diagnosis codes from the Applicable Codes list when submitting claims or PA requests.

Billing Rule

Thermal Intradiscal / Related Procedure Codes

Applicable and commonly used procedure codes for thermal intradiscal and related intradiscal procedures are listed for billing reference. Inclusion of a code here is for reference only and does not indicate coverage. Providers must confirm PA requirements and coverage determination with the member's benefit plan.

Prerequisite Conservative Care Before Intradiscal Interventions

Failure of conservative care prior to consideration in studies

Many studies enrolling patients for surgical or device interventions required prior conservative management failure or contraindication; clinical trial populations commonly required documented failure of nonoperative therapy.

Failure of conservative care prior to consideration in studies: Patients included in key annular closure device trials and many intradiscal procedure studies had persistent symptoms after failure of conservative care or had contraindications to conservative treatment; studies typically required failure of more than 6 weeks of nonoperative therapy.>= 6 weeks

Documented failure of at least 6 weeks of conservative care is typical in trial inclusion criteria and expected for consideration.

Conservative therapy trial prior to consideration of intradiscal interventions

Selection in several intradiscal procedure studies required a longer conservative management trial before enrollment.

Conservative therapy trial prior to consideration of intradiscal interventions:

Imaging and Diagnostic Documentation

Documentation Required

Imaging guidance required — fluoroscopy or CT for TIPs and intradiscal injections

Thermal intradiscal procedures and percutaneous intradiscal injections are performed under fluoroscopic or CT guidance as described in procedural definitions and code descriptors; document imaging guidance used (fluoroscopy or CT) in the record and authorization request.

Image guidance: fluoroscopy or CT depending on procedure
Document guidance modality when applicable

Documentation Required

Imaging selection criteria for IDET/IDB — document provocation discography or MRI findings

Selection criteria used in IDET/IDB and other intradiscal procedure trials often required imaging markers such as preserved disc height (>50% in some studies), positive provocative discography (DDS), or a high‑intensity zone (HIZ) on MRI; document these imaging findings if present when requesting procedures.

Document preserved disc height, positive provocation discography (DDS), or HIZ on MRI as applicable
Trials enrolled patients with these imaging characteristics as predictors of success

Frequency and Repeat Procedure Notes

Annular closure device implantation — frequency limits / repeat placement

Frequency / repeat guidanceNo explicit numeric frequency limits provided; policy lists annular closure device implantation under Frequency Limits but does not specify repeat placement intervals — clinical use follows FDA indication for primary discectomy at a single level (L4–S1) and trial-based selection criteria.

Context for useImplantation is described as an adjunct at time of lumbar microdiscectomy for patients with large annular defects (e.g., 6–10 mm width in key RCT).

Imaging/documentation requirementImaging confirming annular defect size and neural compression (MRI) is required to support device indication per FDA labeling.

Repeat/secondary proceduresRCTs report reduced reoperation for recurrent herniation with ACD versus discectomy alone; policy does not specify allowance or timing for subsequent repeat ACD implantation.

Bipolar radiofrequency thermocoagulation — frequency guidance

Key Terms and Definitions

Annulus fibrosus — definition

DefinitionAnnulus fibrosus: a ring of fibrocartilage and fibrous tissue around the intervertebral disc, surrounding the nucleus pulposus.

Clinical relevanceSurgical discectomy creates an annular defect in the annulus fibrosus that may be targeted by repair devices.

FunctionAnnulus fibrosus provides a flexible wall between the nucleus and surrounding structures; repair devices aim to reinforce or bridge the defect.

Thermal Intradiscal Procedures (TIPs) — definitions

TIPs — generalThermal intradiscal procedures (TIPs) involve insertion of a catheter or probe into the disc under fluoroscopic guidance to apply heat within the disc aiming to reduce low back pain by shrinking collagen, sealing tears, removing unwanted tissue, or destroying nociceptors.

IDET

Clinical Background and Rationale

Background: The annulus fibrosus is the fibrocartilaginous ring that surrounds the nucleus pulposus of the intervertebral disc and may be damaged during discectomy, producing an annular defect. Therapeutic approaches addressed in this policy target annular defects or intradiscal pathology—including mechanical closure with bone‑anchored devices, thermal denaturation or coagulation of intradiscal nociceptors, and injection of donor‑derived cellular/tissue products intended to promote repair.

Services Not Covered / Excluded

Not covered: The following procedures are considered not covered under this policy for the treatment of discogenic pain: annular closure devices (ACDs), percutaneous injection of allogeneic cellular/tissue‑based products, and thermal intradiscal procedures (TIPs) such as IDET, IDB, and PIRFT, except where specific, well‑defined FDA indications or approved research protocols apply.

Clarification: Percutaneous allogeneic intradiscal injections and many thermal intradiscal procedures are not supported by sufficient high‑quality evidence for general coverage and therefore are not covered outside of appropriately designed clinical trials or consistent approved indications.

Supporting statement: Annular closure devices, percutaneous allogeneic intradiscal injections, and thermal intradiscal procedures are each explicitly listed in the policy rationale as unproven and not medically necessary for treating discogenic pain and are therefore excluded from routine coverage.

Additional supportive detail: Evidence for PIRFT and similar intra‑annular thermal therapies includes randomized and placebo‑controlled trials that failed to demonstrate consistent benefit and guideline evaluations (e.g., NICE) that describe limited, low‑quality evidence; consequently these techniques are not supported for routine coverage.

Policy emphasis: Given inconsistent efficacy data across device and intradiscal thermal and biologic injection studies and guideline assessments that call for higher‑quality evidence, these procedures are considered investigational or not medically necessary for routine management of discogenic low back pain.

OpenPayer

Discogenic Pain Treatment (for New Mexico Only)